(AMGN) Amgen - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0311621009
AMGN: Oncology, Bone, Arthritis, Cardiovascular, Immune
Amgen Inc. (NASDAQ:AMGN) is a global biotechnology company specializing in the discovery, development, and delivery of innovative human therapeutics. Its portfolio includes treatments for chronic and severe diseases, such as Enbrel for rheumatoid arthritis and psoriasis, Otezla for plaque psoriasis, and Prolia for osteoporosis. The company also offers Repatha for cardiovascular risk reduction, Nplate for immune thrombocytopenia, and KYPROLIS for multiple myeloma. Additional products include Aranesp for anemia, EVENITY for osteoporosis, Vectibix for colorectal cancer, BLINCYTO for acute lymphoblastic leukemia, TEPEZZA for thyroid eye disease, and KRYSTEXXA for chronic gout. Amgen markets other therapies like Neulasta, MVASI, AMJEVITA, and EPOGEN. The company distributes its products through wholesale distributors and direct-to-consumer channels, serving healthcare providers, clinics, hospitals, and pharmacies.
Amgen collaborates with partners like AstraZeneca for TEZSPIRE, Novartis for Aimovig, UCB for EVENITY, Kyowa Kirin for rocatinlimab, and BeiGene for oncology products. Incorporated in 1980, the company is headquartered in Thousand Oaks, California. Its strategic partnerships and robust R&D pipeline position it as a leader in the biotechnology sector, with a focus on addressing unmet medical needs and improving patient outcomes.
Additional Sources for AMGN Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AMGN Stock Overview
| Market Cap in USD | 149,085m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 1983-06-17 |
AMGN Stock Ratings
| Growth Rating | 34.5 |
| Fundamental | 44.3 |
| Dividend Rating | 74.4 |
| Rel. Strength | 11.9 |
| Analysts | 3.59/5 |
| Fair Price Momentum | 278.49 USD |
| Fair Price DCF | 425.25 USD |
AMGN Dividends
| Dividend Yield 12m | 3.95% |
| Yield on Cost 5y | 5.54% |
| Annual Growth 5y | 7.06% |
| Payout Consistency | 100.0% |
AMGN Growth Ratios
| Growth Correlation 3m | 9.8% |
| Growth Correlation 12m | -22.5% |
| Growth Correlation 5y | 84.1% |
| CAGR 5y | 5.98% |
| CAGR/Max DD 5y | 0.24 |
| Sharpe Ratio 12m | 0.54 |
| Alpha | -0.68 |
| Beta | 0.386 |
| Volatility | 24.82% |
| Current Volume | 2679.6k |
| Average Volume 20d | 2861k |
As of April 24, 2025, the stock is trading at USD 277.90 with a total of 2,679,592 shares traded.
Over the past week, the price has changed by -1.68%, over one month by -11.60%, over three months by +0.82% and over the past year by +4.69%.
Partly, yes. Based on ValueRay Fundamental Analyses, Amgen (NASDAQ:AMGN) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 44.34 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMGN as of April 2025 is 278.49. This means that AMGN is currently overvalued and has a potential downside of 0.21%.
Amgen has received a consensus analysts rating of 3.59. Therefor, it is recommend to hold AMGN.
- Strong Buy: 10
- Buy: 4
- Hold: 15
- Sell: 1
- Strong Sell: 2
According to ValueRays Forecast Model, AMGN Amgen will be worth about 300.8 in April 2026. The stock is currently trading at 277.90. This means that the stock has a potential upside of +8.23%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 317.1 | 14.1% |
| Analysts Target Price | 319.4 | 14.9% |
| ValueRay Target Price | 300.8 | 8.2% |